In the present study, we showed a novel cardioprotective effect of trimetazidine against the pressure overload-induced CHF through enhancing the activation of AMPK, by which trimetazidine improved the insulin sensitivity and resultantly relieved mitochondrial dysfunction (Figure 7). The gene discussed is INS; the disease is congestive heart failure.